Lv6
2410 积分 2025-03-26 加入
Interleukin-6 Inhibition with Ziltivekimab in Chronic Kidney Disease–Associated Anemia: A Hypothesis-Generating Systematic Review and Meta-Analysis of Early-Phase Randomized Trials
1天前
已完结
Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?
1天前
已完结
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
2天前
已完结
C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden
2天前
已完结
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
2天前
已完结
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial
2天前
已完结
Systemic Inflammation and Recurrence After Atrial Fibrillation–Related Stroke
2天前
已完结
Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial
2天前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
2天前
已完结
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
2天前
已完结
皖公网安备34019202002308
